A study of an experimental psychedelic for depression
Treatments studied
Part of Mental health clinical trials.
This trial tests an experimental psychedelic-like drug, CYB003, to see if it can help people with depression who haven't gotten enough relief from their current antidepressant. You would receive the study drug during a supervised session, with psychological support.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have been diagnosed with moderate-to-severe depression (single episode lasting 4 weeks to 2 years, or recurrent).
- You are currently taking one antidepressant medication at a stable dose for at least the past month, but it hasn't helped enough.
- You have not tried two or more different antidepressant types that failed (this is for people who haven't had treatment-resistant depression).
- You have used psychedelics 10 times or fewer in your lifetime and none in the past year.
- You are not at immediate risk of suicide or self-harm, and you do not have a history of bipolar or psychotic disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This long-term study is for people who already completed an earlier trial of the experimental drug CYB003 for major depression and who stayed on their regular antidepressant. It looks at the safety and effects of taking CYB003 again over many months.
This study tests an investigational drug called BMS-986511 in adults with moderate to severe depression. The goal is to see if it can improve symptoms.
This trial tests a single dose of an investigational drug (CYB003) in people with depression and anxiety who haven't gotten enough help from their current antidepressant. You would take a psilocybin-like medication and be monitored for how it affects your mood and anxiety.
This study tests whether a single dose of psilocybin (a psychedelic compound) can help treat depression by looking at brain changes on MRI. It is designed for people with moderate-to-severe depression who have not responded well to other treatments.
This trial tests an investigational drug called NBI-1065845 added to your current antidepressant. It is for people with moderate to severe depression or persistent depressive disorder who have not improved enough with oral antidepressants alone.
This trial tests a new medication called NBI-1065845 added to your current antidepressant for people with depression that hasn't fully responded to treatment. It aims to see if this combination can better improve your symptoms.
Hear when a new Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.